Cardiac hypertrophy, characterized by the enlargement of cardiomyocytes, is initially an adaptive response to physiological and pathological stimuli. Decompensated cardiac hypertrophy is related to fibrosis, inflammatory cytokine, maladaptive remodeling, and heart failure. Although pathological myocardial hypertrophy is the main cause of hypertrophy-related morbidity and mortality, our understanding of its mechanism is still poor. Long noncoding RNAs (lncRNAs) are noncoding RNAs that regulate various physiological and pathological processes through multiple molecular mechanisms. Recently, accumulating evidence has indicated that lncRNA-H19 is a potent regulator of the progression of cardiac hypertrophy. For the first time, this review summarizes the current studies about the role of lncRNA-H19 in cardiac hypertrophy, including its pathophysiological processes and underlying pathological mechanism, including calcium regulation, fibrosis, apoptosis, angiogenesis, inflammation, and methylation. The context within which lncRNA-H19 might be developed as a target for cardiac hypertrophy treatment is then discussed to gain better insight into the possible biological functions of lncRNA-H19 in cardiac hypertrophy.

中文翻译：

---

LncRNA-H19在心肌肥厚中的作用

以心肌细胞增大为特征的心脏肥大最初是对生理和病理刺激的适应性反应。失代偿性心脏肥大与纤维化、炎性细胞因子、适应不良重构和心力衰竭有关。尽管病理性心肌肥厚是肥厚相关发病率和死亡率的主要原因，但我们对其机制的了解仍然很差。长链非编码 RNA (lncRNA) 是通过多种分子机制调节各种生理和病理过程的非编码 RNA。最近，越来越多的证据表明 lncRNA-H19 是心脏肥大进展的有效调节剂。本综述首次总结了目前关于lncRNA-H19在心肌肥厚中作用的研究，包括其病理生理过程和潜在的病理机制，包括钙调节、纤维化、细胞凋亡、血管生成、炎症和甲基化。然后讨论了 lncRNA-H19 可能被开发为心脏肥大治疗靶点的背景，以更好地了解 lncRNA-H19 在心脏肥大中可能的生物学功能。